collection
MENU ▼
Read by QxMD icon Read
search

Lung cancer

shared collection
31 papers 100 to 500 followers
By Robert Zielinski Medical oncologist in orange NSE
https://www.readbyqxmd.com/read/27751847/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung-cancer-aura2-a-multicentre-open-label-single-arm-phase-2-study
#1
Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee-Chen Chang, Lucio Crino, Miyako Satouchi, Quincy Chu, Toyoaki Hida, Ji-Youn Han, Oscar Juan, Frank Dunphy, Makoto Nishio, Jin-Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi
BACKGROUND: Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an approved EGFR tyrosine-kinase inhibitor. METHODS: In this phase 2, open-label, single-arm study (AURA2), patients aged at least 18 years with centrally confirmed EGFR Thr790Met-positive mutations, locally advanced or metastatic (stage IIIB/IV) NSCLC who progressed on previous EGFR tyrosine-kinase inhibitor therapy received osimertinib 80 mg orally once daily; treatment could continue beyond progression if the investigator observed a clinical benefit...
October 14, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27022112/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with-previously-treated-advanced-lung-adenocarcinoma-wjog-5108l
#2
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, Reiko Kaji, Hiroshige Yoshioka, Takashi Seto, Miyako Satouchi, Yasuo Iwamoto, Masashi Kanehara, Daichi Fujimoto, Norihiko Ikeda, Haruyasu Murakami, Haruko Daga, Tetsuya Oguri, Isao Goto, Fumio Imamura, Shunichi Sugawara, Hideo Saka, Naoyuki Nogami, Shunichi Negoro, Kazuhiko Nakagawa, Yoichi Nakanishi
PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors (TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-generation EGFR-TKIs. This randomized phase III study was conducted to investigate the difference between these two EGFR-TKIs. PATIENTS AND METHODS: Previously treated patients with lung adenocarcinoma were randomly assigned to receive gefitinib or erlotinib...
September 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27718847/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer
#3
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer
Background Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy...
October 8, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26712084/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced-non-small-cell-lung-cancer-keynote-010-a-randomised-controlled-trial
#4
RANDOMIZED CONTROLLED TRIAL
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon
BACKGROUND: Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. METHODS: We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks...
April 9, 2016: Lancet
https://www.readbyqxmd.com/read/27177600/changing-trends-in-diagnosis-staging-treatment-and-survival-in-lung-cancer-comparison-of-three-consecutive-cohorts-in-an-australian-lung-cancer-centre
#5
E J Denton, D Hart, Z Wainer, G Wright, P A Russell, M Conron
BACKGROUND: Lung cancer accounts for significant morbidity and mortality worldwide. The effect of recent changes in demographics and management on outcomes in Australia has not been clearly defined. AIMS: To compare three consecutive lung cancer cohorts to evaluate emergent differences in diagnosis, management and mortality. METHODS: For comparative analysis, 2119 lung cancer patients were divided into three successive cohorts. Current death data were sought from the Victorian Cancer Registry...
August 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27574741/lung-cancer-current-therapies-and-new-targeted-treatments
#6
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies...
August 26, 2016: Lancet
https://www.readbyqxmd.com/read/26944304/the-iaslc-lung-cancer-staging-project-background-data-and-proposed-criteria-to-distinguish-separate-primary-lung-cancers-from-metastatic-foci-in-patients-with-two-lung-tumors-in-the-forthcoming-eighth-edition-of-the-tnm-classification-for-lung-cancer
#7
Frank C Detterbeck, Wilbur A Franklin, Andrew G Nicholson, Nicolas Girard, Douglas A Arenberg, William D Travis, Peter J Mazzone, Edith M Marom, Jessica S Donington, Lynn T Tanoue, Valerie W Rusch, Hisao Asamura, Ramón Rami-Porta
INTRODUCTION: It can be difficult to distinguish between a second primary and a metastasis in patients with lung cancer who have more than one pulmonary site of cancer. METHODS: A systematic review of the literature was conducted by a subcommittee of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee to develop recommendations to identify second primary lung cancers. The process entailed review of knowledge relating to the mechanism of metastasis, determination of clonality, and outcomes of patients with resected tumors...
May 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/25230595/use-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer-a-phase-3-randomised-controlled-trial
#8
RANDOMIZED CONTROLLED TRIAL
Ben J Slotman, Harm van Tinteren, John O Praag, Joost L Knegjens, Sherif Y El Sharouni, Matthew Hatton, Astrid Keijser, Corinne Faivre-Finn, Suresh Senan
BACKGROUND: Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment of this patient group. METHODS: We did this phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in Norway, and one in Belgium. We enrolled patients with WHO performance score 0-2 and confirmed ES-SCLC who responded to chemotherapy...
January 3, 2015: Lancet
https://www.readbyqxmd.com/read/21864934/metastatectomy-for-extra-cranial-extra-adrenal-non-small-cell-lung-cancer-solitary-metastases-systematic-review-and-analysis-of-reported-cases
#9
REVIEW
Samer Salah, Tawee Tanvetyanon, Salah Abbasi
BACKGROUND: Although patients with stage IV non-small cell lung cancer (NSCLC) have a poor prognosis, a subset of patients with solitary brain or adrenal metastasis have more favorable outcome following surgical resection. Nevertheless, the outcome and predictive factors for survival following metastatectomy for patients with other metastatic sites are not well defined. METHODS: We performed a systematic review using PUBMED database for all articles which included patients with NSCLC and solitary metastasis to sites other than the adrenal gland or the brain who had undergone resection of their metastasis and definitive treatment of the primary lung cancer...
January 2012: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/18439766/impact-of-postoperative-radiation-therapy-on-survival-in-patients-with-complete-resection-and-stage-i-ii-or-iiia-non-small-cell-lung-cancer-treated-with-adjuvant-chemotherapy-the-adjuvant-navelbine-international-trialist-association-anita-randomized-trial
#10
RANDOMIZED CONTROLLED TRIAL
Jean-Yves Douillard, Rafael Rosell, Mario De Lena, Marcello Riggi, Patrick Hurteloup, Marc-Andre Mahe
PURPOSE: To study the impact of postoperative radiation therapy (PORT) on survival in the Adjuvant Navelbine International Trialist Association (ANITA) randomized study of adjuvant chemotherapy. METHODS AND MATERIALS: ANITA is a randomized trial of adjuvant cisplatin and vinorelbine chemotherapy vs. observation in completely resected non-small-cell lung carcinoma (NSCLC) Stages IB to IIIA. Use of PORT was recommended for pN+ disease but was not randomized or mandatory...
November 1, 2008: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26275735/induction-chemoradiation-in-stage-iiia-n2-non-small-cell-lung-cancer-a-phase-3-randomised-trial
#11
RANDOMIZED CONTROLLED TRIAL
Miklos Pless, Roger Stupp, Hans-Beat Ris, Rolf A Stahel, Walter Weder, Sandra Thierstein, Marie-Aline Gerard, Alexandros Xyrafas, Martin Früh, Richard Cathomas, Alfred Zippelius, Arnaud Roth, Milorad Bijelovic, Adrian Ochsenbein, Urs R Meier, Christoph Mamot, Daniel Rauch, Oliver Gautschi, Daniel C Betticher, René-Olivier Mirimanoff, Solange Peters
BACKGROUND: One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate whether the addition of neoadjuvant radiotherapy improves outcomes. METHODS: We enrolled patients in 23 centres in Switzerland, Germany and Serbia. Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were randomly assigned to treatment groups in a 1:1 ratio...
September 12, 2015: Lancet
https://www.readbyqxmd.com/read/25811445/fdg-uptake-on-positron-emission-tomography-correlates-with-survival-and-time-to-recurrence-in-patients-with-stage-i-non-small-cell-lung-cancer
#12
Woocheol Kwon, Brandon A Howard, James E Herndon, Edward F Patz
INTRODUCTION: Patients with stage I non-small-cell lung cancer (NSCLC) have a wide variation in outcomes, most likely because there are undetected metastases at presentation. We retrospectively reviewed patients with early stage lung cancer to determine if FDG uptake of the primary tumor as measured on positron emission tomography (PET) at the time of diagnosis was associated with overall survival (OS) or time to recurrence (TTR). METHODS: We reviewed the Tumor Registry at our institution and identified 336 consecutive patients diagnosed with stage I NSCLC over a 5-year period who underwent an FDG-PET/computed tomography within 90 days before surgery...
June 2015: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/21498541/correlation-between-18f-fdg-uptake-on-pet-and-molecular-biology-in-metastatic-pulmonary-tumors
#13
Kyoichi Kaira, Takehiro Okumura, Yasuhisa Ohde, Toshiaki Takahashi, Haruyasu Murakami, Noboru Oriuchi, Masahiro Endo, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto
UNLABELLED: (18)F-FDG PET can help in predicting therapeutic response and outcome in patients with metastatic pulmonary tumors. However, no satisfactory biologic explanation exists for this phenomenon. The aim of this study was to investigate the underlying biologic mechanisms of (18)F-FDG uptake in metastatic pulmonary tumors. METHODS: One hundred forty-six patients with metastatic pulmonary tumors who underwent (18)F-FDG PET before treatment were included in this study...
May 2011: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/26001140/stereotactic-ablative-radiation-therapy-for-the-treatment-of-early-stage-non-small-cell-lung-cancer-cepo-review-and-recommendations
#14
REVIEW
Gino Boily, Édith Filion, George Rakovich, Neil Kopek, Lise Tremblay, Benoit Samson, Stéphanie Goulet, Isabelle Roy
BACKGROUND: Lung cancer is the second most diagnosed cancer and the leading cause of cancer-related mortality in Canada. Surgical resection is the treatment of choice for patients with stage I non-small-cell lung cancer (NSCLC). However, 20% to 30% of them are deemed medically inoperable and may be offered radiation therapy. Standard external-beam radiation therapy (EBRT) is associated with high rates of local recurrence and poor long-term survival. Stereotactic ablative radiation therapy (SABR) is increasingly being proposed for inoperable patients, and the use of this treatment modality for operable patients is also being contemplated...
June 2015: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/23724913/crizotinib-versus-chemotherapy-in-advanced-alk-positive-lung-cancer
#15
RANDOMIZED CONTROLLED TRIAL
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J O'Byrne, Denis Moro-Sibilot, D Ross Camidge, Tony Mok, Vera Hirsh, Gregory J Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D Wilner, Pasi A Jänne
BACKGROUND: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown. METHODS: We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen...
June 20, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/25981817/sabr-in-early-operable-lung-cancer-time-for-evidence
#16
COMMENT
Tom Treasure, Robert C Rintoul, Fergus Macbeth
No abstract text is available yet for this article.
June 2015: Lancet Oncology
https://www.readbyqxmd.com/read/17047644/palliative-chemotherapy-beyond-three-courses-conveys-no-survival-or-consistent-quality-of-life-benefits-in-advanced-non-small-cell-lung-cancer
#17
RANDOMIZED CONTROLLED TRIAL
C von Plessen, B Bergman, O Andresen, R M Bremnes, S Sundstrom, M Gilleryd, R Stephens, J Vilsvik, U Aasebo, S Sorenson
This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We compared a policy of three vs six courses of new-generation platinum-based combination chemotherapy with regard to effects on quality of life (QoL) and survival. Patients with stage IIIB or IV NSCLC and WHO performance status (PS) 0-2 were randomised to receive three (C3) or six (C6) courses of carboplatin (area under the curve (AUC) 4, Chatelut's formula, equivalent to Calvert's AUC 5) on day 1 and vinorelbine 25 mg m(-2) on days 1 and 8 of a 3-week cycle...
October 23, 2006: British Journal of Cancer
https://www.readbyqxmd.com/read/11230476/duration-of-chemotherapy-in-advanced-non-small-cell-lung-cancer-a-randomized-trial-of-three-versus-six-courses-of-mitomycin-vinblastine-and-cisplatin
#18
RANDOMIZED CONTROLLED TRIAL
I E Smith, M E O'Brien, D C Talbot, M C Nicolson, J L Mansi, T F Hickish, A Norton, S Ashley
PURPOSE: So far there are no published data on optimal duration of chemotherapy for advanced non-small-cell lung cancer (NSCLC); six or more courses are usually recommended. We have carried out a multicenter randomized trial comparing three versus six courses of chemotherapy. PATIENTS AND METHODS: Patients with stage IIIb or IV NSCLC were randomized at start of treatment to receive either three or six courses of mitomycin 8 mg/m(2) (courses 1, 2, 4, and 6), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) (MVP) every 21 days...
March 1, 2001: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/24669016/2nd-esmo-consensus-conference-on-lung-cancer-non-small-cell-lung-cancer-first-line-second-and-further-lines-of-treatment-in-advanced-disease
#19
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson, L Paz-Ares, M Reck, E F Smit, K Syrigos, R Stahel, E Felip, S Peters
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease...
August 2014: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/25611227/endobronchial-ultrasound-versus-mediastinoscopy-for-mediastinal-nodal-staging-of-non-small-cell-lung-cancer
#20
Sang-Won Um, Hong Kwan Kim, Sin-Ho Jung, Joungho Han, Kyung Jong Lee, Hye Yun Park, Yong Soo Choi, Young Mog Shim, Myung-Ju Ahn, Keunchil Park, Yong Chan Ahn, Joon Young Choi, Kyung Soo Lee, Gee Young Suh, Man Pyo Chung, O Jung Kwon, Jhingook Kim, Hojoong Kim
INTRODUCTION: Correct mediastinal staging is critical for determination of the most appropriate management strategy in patients with non-small-cell lung cancer (NSCLC). The purpose of this study was to compare the diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) with that of mediastinoscopy in patients with NSCLC. METHODS: A prospective trial was conducted in a tertiary referral center in Korea. Patients with histologically proven NSCLC and suspicion for N1, N2, or N3 metastasis were enrolled...
February 2015: Journal of Thoracic Oncology
label_collection
label_collection
1706
1
2
2015-02-22 23:57:37
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"